Skip to Content

Video: BRUKINSA® (Zanubrutinib) for Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Published Date: April 16, 2025

This NCODA educational resource offers an expert-led overview of current treatment advances in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)—focusing specifically on the role of the targeted oral agent, zanubrutinib (Brukinsa). The discussion provides key insights into clinical trial data, safety, dosing, and real-world patient management considerations, making it a valuable resource for oncology pharmacy professionals and care teams.

Topics covered include:

  • Overview of CLL/SLL disease progression and treatment pathways
  • FDA-approved use and mechanism of action of zanubrutinib
  • Results from pivotal clinical trials (SEQUOIA and ALPINE)
  • Practical dosing strategies, drug interactions, and administration guidance
  • Common toxicities and monitoring recommendations
  • Considerations for individualized patient care

 

View Prescribing Information

Sponsored by